Local treatment of chronic osteomyelitis with surgical debridement and tigecycline-impregnated calcium hydroxyapatite: an experimental study

Kaya, Mükerrem; Şimşek-Kaya, Göksel; Gürsan, Nesrin; Kıreçcı, Ekrem; Dayı, Ertunç; Gündoğdu, Betül

doi:10.1016/j.tripleo.2011.03.032

Cited by 16 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high volume of distribution and tissue penetrance further make this agent appealing in difficult-to-penetrate anatomical sites, particularly less vascularized tissue such as bone (Giamarellou & Poulakou, 2011;Ji et al, 2008). Regarding bone infection specifically, animal studies have in fact indicated high eradication rates of susceptible bacteria in osseous tissue when tigecycline is locally implanted (Kaya et al, 2012) or systemically administered (Kandemir et al, 2008). Two case reports in humans have further documented success in treating osteomyelitis due to a resistant Klebsiella isolate (Chen et al, 2010) and a multidrug-resistant Acinetobacter species (Schafer & Mangino, 2008), respectively, while another has suggested the efficacy of tigecycline and colistin employed concomitantly to combat a bone infection caused by a resistant Pseudomonas aeruginosa (Stanzani et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database

Griffin

Harting

Christensen

2013

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database

Griffin

Harting

Christensen

2013

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

“…In view of this, it appears more reasonable to expose indirectly the root surface to DOX by loading it to a delivery vehicle like β‐TCP bone substitute. Several studies have suggested the use of hydroxyapatite (HA) as a drug carrier because of its adequate mechanical properties and composition similarity to bone mineral 10,54‐57 . The porous structure provided by HA, with high surface areas, facilitated sustained release of the tested antibiotics.…”

Section: Discussionmentioning

confidence: 99%

“…β‐TCP is known to have a higher dissolution rate in the physiologic environment, thus increasing in vivo resorbability 58,59 . DOX was loaded into β‐TCP by adsorption behavior of the antibiotic onto calcium phosphate granules 56 . By mixing DOX with β‐TCP, we can also avoid the creation of a DOX gel smear‐like effect over the root surface, obscuring the positive effects of the EDTA‐exposed dentinal tubules and dentin‐associated collagen.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Doxycycline‐Loaded β‐Tricalcium Phosphate Release Following EDTA Root Surface Etching Improved the Clinical Outcomes in Chronic Periodontitis: An In Vivo Study

Gamal

Kumper

Gendy

2013

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…In addition, case reports suggest the potential for quinupristin-dalfopristin the first parenteral streptogramin and tigecycline, a novel parenteral glycylcycline to cure chronic osteomyelitis, but clinical data are limited (Fraimow, 2009;Kaya et al, 2011;Pawar, Bhandari, 2011). Long-term safety and efficacy data needs to be produced with regard to the use of these promising newer agents for treating osteomyelitis due to MRSA and vancomycin-resistant Enterococcus (VRE).…”

Section: New Agentsmentioning

confidence: 99%

Osteomyelitis: an overview of antimicrobial therapy

Gomes

Pereira

Bettencourt

2013

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Osteomyelitis is an inflammatory bone disorder caused by infection, leading to necrosis and destruction of bone. It can affect all ages, involve any bone, become a chronic disease and cause persistent morbidity. Treatment of osteomyelitis is challenging particularly when complex multiresistant bacterial biofilm has already been established. Bacteria in biofilm persist in a low metabolic phase, causing persistent infection due to increased resistance to antibiotics. Staphylococcus aureus and Staphylococcus epidermidis are the most common causative organism responsible for more than 50% of osteomyelitis cases. Osteomyelitis treatment implies the administration of high doses of antibiotics (AB) by means of endovenous and oral routes and should take a period of at least 6 weeks. Local drug delivery systems, using non-biodegradable (polymethylmethacrylate) or biodegradable and osteoactive materials such as calcium orthophosphates bone cements, have been shown to be promising alternatives for the treatment of osteomyelitis. These systems allow the local delivery of AB in situ with bactericidal concentrations for long periods of time and without the toxicity associated with other means of administration. This review examines the most recent literature evidence on the causes, pathogeneses and pharmacological treatment of osteomyelitis. A osteomielite é um processo inflamatório do tecido ósseo, de origem infecciosa, que resulta em destruição inflamatória, necrose e formação de novo osso. Pode aparecer em qualquer idade, afetar qualquer osso e tornar-se uma doença crônica com morbidade persistente. Apesar dos progressos na quimioterapia infecciosa, o tratamento da osteomielite é caro e difícil, em particular quando associada à presença de biofilmes bacterianos, especialmente de Staphylococcus aureus e Staphylococcus epidermidis. O tratamento da osteomielite inclui a administração de doses elevadas de antibióticos (AB) por via endovenosa e oral, durante um período de pelo menos 6 semanas. Os sistemas de veiculação localizada de fármacos, utilizando materiais não biodegradáveis (polimetilmetacrilato) ou biodegradáveis e osteoativos como os cimentos ósseos de ortofosfatos de cálcio e vidro bioativo, surgiram como uma alternativa promissora para o tratamento da osteomielite. Estes sistemas permitem a veiculação de AB in situ com concentrações bactericidas por longos períodos de tempo e sem a toxicidade associada às outras vias de administração. O presente trabalho propõe uma revisão da literatura relativa às causas, à patogenia e ao tratamento farmacológico da osteomielite. A metodologia do estudo da revisão consistiu numa pesquisa bibliográfica, nas bases de dados Google Scholar, Science Direct, Pubmed, Springer link, B-on. Foram revistos e analisados diversos artigos publicados desde o ano de 1979.Unitermos: Osteomielite/tratamento farmacológico. Osteomielite/terapia antimicrobial. Staphylococcus aureus/presença/osteomielite. Antibióticos/uso/tratamento da osteomielite.

show abstract

Local treatment of chronic osteomyelitis with surgical debridement and tigecycline-impregnated calcium hydroxyapatite: an experimental study

Cited by 16 publications

References 34 publications

Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database

Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database

Doxycycline‐Loaded β‐Tricalcium Phosphate Release Following EDTA Root Surface Etching Improved the Clinical Outcomes in Chronic Periodontitis: An In Vivo Study

Osteomyelitis: an overview of antimicrobial therapy

Contact Info

Product

Resources

About